Forte Biosciences, Inc.
FBRX
$18.31
-$0.78-4.09%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 7.53% | -13.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 58.76% | -28.19% | |||
| Operating Income | -58.76% | 28.19% | |||
| Income Before Tax | -57.19% | 28.15% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -57.19% | 28.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -57.19% | 28.15% | |||
| EBIT | -58.76% | 28.19% | |||
| EBITDA | -58.82% | 28.22% | |||
| EPS Basic | -3.75% | 30.27% | |||
| Normalized Basic EPS | -3.76% | 30.27% | |||
| EPS Diluted | -3.75% | 30.27% | |||
| Normalized Diluted EPS | -3.76% | 30.27% | |||
| Average Basic Shares Outstanding | 51.51% | 3.03% | |||
| Average Diluted Shares Outstanding | 51.51% | 3.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||